Compare MPAA & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPAA | TTRX |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.7M | 281.2M |
| IPO Year | 2007 | N/A |
| Metric | MPAA | TTRX |
|---|---|---|
| Price | $13.87 | $10.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.50 | $8.00 |
| AVG Volume (30 Days) | 82.5K | ★ 90.4K |
| Earning Date | 06-08-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 162.63 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $789,806,000.00 | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | ★ 4.28 | N/A |
| 52 Week Low | $9.29 | $2.57 |
| 52 Week High | $18.12 | $11.69 |
| Indicator | MPAA | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 61.26 |
| Support Level | $13.51 | $2.95 |
| Resistance Level | $13.81 | $10.48 |
| Average True Range (ATR) | 0.62 | 0.84 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 24.50 | 73.76 |
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts, test solutions, and diagnostic equipment. Its replacement parts are mainly sold to automotive retail chain stores, warehouse distributors across North America, and automobile manufacturers for aftermarket and warranty replacement programs. The Company's test solutions and diagnostic equipment serve the automotive component and powertrain testing market. Its product portfolio includes rotating electrical products such as alternators and starters; brake-related products including brake calipers, brake rotors, brake pads, brake master cylinders, and wheel hub assemblies and bearings; and other products. Its segments are Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.